Literature DB >> 2371973

Ki-67 labeling index is a more reliable measure of solid tumor proliferative activity than tritiated thymidine labeling.

P Deshmukh1, L Ramsey, H S Garewal.   

Abstract

The proliferative activity of tumors has been shown to have prognostic significance in a variety of solid tumors. The standard method for assessing the proliferating fraction has been the measurement of the tritiated thymidine labeling index (TLI). Ki-67 is a monoclonal antibody that labels proliferating cells. In this study, the authors compared the proliferative activity of seven solid tumor specimens, using both methods simultaneously, on comparable sections from the same specimen. As expected, in every case the Ki-67 labeling index (KiLI) was greater than the TLI. The mean TLI ranged from 4.4 +/- 0.4% to 16.7 +/- 10.2%. The KiLI from these same tumors ranged from 25.7 +/- 8.6% to 41.2 +/- 12.2%. The mean coefficient of variation for measurements from different sections within the same specimen was 28.8 for TLI and 16.4 for KiLI. Therefore, KiLI shows less variability within different sections of the same specimen and is, therefore, a more reliable marker for proliferative activity than is TLI.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2371973     DOI: 10.1093/ajcp/94.2.192

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  6 in total

1.  Can Ki67 immunostaining predict response to radiotherapy in oral squamous cell carcinoma?

Authors:  G Valente; R Orecchia; S Gandolfo; M Arnaudo; R Ragona; S Kerim; G Palestro
Journal:  J Clin Pathol       Date:  1994-02       Impact factor: 3.411

2.  Prognostic significance of Ki-67 expression for patients with laryngeal squamous cell carcinoma primarily treated by total laryngectomy.

Authors:  Mustafa Fuat Acikalin; Ulkü Oner; Nilüfer Tel; Ozgül Paşaoğlu; Hamdi Cakli; Ertuğrul Colak
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-11-06       Impact factor: 2.503

3.  Tumor proliferative activity and response to first-line chemotherapy in advanced breast carcinoma.

Authors:  A Bonetti; M Zaninelli; S Rodella; A Molino; L Sperotto; Q Piubello; F Bonetti; R Nortilli; M Turazza; G L Cetto
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

4.  DNA Topoisomerase II-alpha as a marker of cell proliferation in endocrine and other neoplasms.

Authors:  J A Holden
Journal:  Endocr Pathol       Date:  1999-06       Impact factor: 3.943

5.  Prognostic impact of Ki-67 in patients with gastric cancer-the importance of depth of invasion and histologic differentiation.

Authors:  Gyung Hyuck Ko; Se-Il Go; Won Sup Lee; Jeong-Hee Lee; Sang-Ho Jeong; Young-Joon Lee; Soon Chan Hong; Woo Song Ha
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

6.  The Use of CD44 Variant 9 and Ki-67 Combination Can Predicts Prognosis Better Than Their Single Use in Early Gastric Cancer.

Authors:  Se-Il Go; Gyung Hyuck Ko; Won Sup Lee; Jeong-Hee Lee; Sang-Ho Jeong; Young-Joon Lee; Soon Chan Hong; Woo Song Ha
Journal:  Cancer Res Treat       Date:  2019-02-25       Impact factor: 4.679

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.